Business
Half Yearly Report to 31 March 2017
Half Yearly Report to 31 March 2017.
About this update from Ixico Plc
[{"type":"text","content":"\n \nRNS Number : 7225F IXICO plc 22 May 2017 \n\nIXICO plc\n(\"IXICO\", the \"Company\" or the \"Group\")\n \nHalf Yearly Report to 31 March 2017\n \nStrong revenue growth\nDelivering on contracts and commercial collaborations \n \n22 May 2017, IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, announces its unaudited interim results for the six months ended 31 March 2017.\n \nFinancial Highlights\n· Revenue increased by 31% to £2.0m (2016: £1.5m)\n· Improved gross profit margin performance of 56% (2016: 49%)\n· EBITDA loss reduced to £0.4m (2016: £1.0m)\n· Operating loss reduced to £0.8m (2016: £1.1m)\n· Loss per share reduced to 2.6p (2016: 4.6p)\n· Cash balance of £2.8m (2016: £3.2m) \n \nCommercial and Operational Highlights \nBoard restructuring\n· Giulio Cerroni appointed as Chief Executive Officer, brings extensive experience in scaling operations to build businesses and supplying sophisticated products and services to pharmaceutical and research life science markets\n· Derek Hill remains on the Board as President of Regulatory Science and External Relations with specific responsibility for deepening the Company's relationships with major pharmaceutical companies\n \nFurther strengthening of IXICO's specialist digital services to pharmaceutical customers\n· Assessa®PML collaboration with Biogen expanded from pilot stage to planning production roll-out\n· New sales wins demonstrate continued expansion and success in neurological disease areas\n· New contract with existing top 10 pharmaceutical company reflects increasing adoption of technology platform\n \nInnovation remains a key pillar of our long term strategy \n· Participation in a leading research collaboration to assess β-amyloid for the prevention of Alzheimer's Disease as part of the EPAD consortium\n· Participation in a new collaborative pan-European research effort focused on addressing the challenges of successfully delivering therapies to people with Alzheimer's Disease as part of the ROA...